非小细胞肺癌药物治疗进展与展望  

Progress and prospect of drug therapy in non-small-cell lung cancer

作　　者：陈培欣 周彩存[1] Chen Peixin;Zhou Caicun(School of Medicine,Tongji University,Department of Medical Oncology,Shanghai Pulmonary Hospital,Tongji University,Shanghai 200000,China)

机构地区：[1]同济大学医学院,同济大学附属上海市肺科医院肿瘤科,上海200000

出　　处：《实用肿瘤杂志》2022年第1期33-39,共7页Journal of Practical Oncology

摘　　要：肺癌是生物医学领域亟需攻克的难题之一。近年来,治疗非小细胞肺癌(non-small-cell lung cancer,NSCLC)的药物迅速发展,展现出巨大的临床应用和发展潜力。本文将从围手术期、不可切除局部晚期、驱动基因阳性晚期和驱动基因阴性晚期四个方面,回顾国内外NSCLC药物治疗的进展,同时对NSCLC药物发展中存在的问题与挑战进行总结与展望,以期为临床肿瘤科医师提供参考和指导。;Lung cancer is one of the most challenging problems in the field of biomedicine.In recent years,with the rapid development of drug therapy in non-small-cell lung cancer(NSCLC),an increasing number of drugs have shown giant potential and value in clinical application.This review summarizes the progress,problems and challenges of drug therapy in NSCLC from four aspects,including perioperative NSCLC,locally advanced/unresectable NSCLC,advanced NSCLC with oncogene driver alteration,and advanced NSCLC without oncogene driver alteration,so as to provide up-to-date references and guidance for clinical oncologists.

关 键 词：非小细胞肺癌 围手术期 不可切除局部晚期 驱动基因 

分 类 号：R734.2[医药卫生—肿瘤]